Kewill's flagging share price received a much-needed boost on account of a positive trading update. Over the past 12 months the shares have slumped from a high of just over £10 to current levels, bottoming out at 30p in mid-September following a profit warning and the terrorist attacks on New York and Washington. The profit warning, which was delivered in August, saw supply-chain-management solutions business Kewill admit that sales in the first four months had been 'substantially below expectations' and that full year profitability was highly unlikely unless conditions dramatically improved. As a result of this statement broker forecasts were slashed. Market consensus had originally predicted that Kewill would continue to build on the success of last year, when pre-tax profits leapt 83% to £3.3m, with a profit in the region of £6.5m expected. Losses of around £5m are now being touted. Kewill's most recent update confirmed that first half figures are likely to be in line with these revised estimates, but stated that performance in the second quarter had shown a 'substantial improvement'. Although the dramatic improvement remains highly unlikely, management holds the belief that second half breakeven, at the operating level, is a distinct possibility.
Market cap: £32.1m
PE Forecast: n/a
Share price: 42p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.